id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-307287-zpq6byml	Poulsen, Nadia Nicholine	Cyclosporine and COVID‐19: Risk or Favorable?	2020-08-10		.txt	text/plain	4455	235	39	A letter by Russel et al suggests that there is tantalizing in vitro evidence for cyclosporine as an anti-coronavirus agent as well as a potential disease-modifying role through inhibition of Severe Acute Respiratory Syndrome (SARS) coronavirus-mediated IL-2 induction and authors advocate that a trial of cyclosporine should be considered in the event of a future SARS epidemic 22 . The Immunonephrology Working Group of the European Renal Association-European Dialysis and Transplant Association has published recommendations for the management of patients with immune-mediated kidney disease during this current pandemic, and authors point out that patients with mild COVID-19 might continue low dose of cyclosporine due to the in vitro evidence of inhibition of coronavirus replication 84 . We are still awaiting robust data from COVID-19 patients actively treated with calcineurin inhibitors due to transplantation or autoimmune diseases but so far there is no evidence that use of cyclosporine possess an additional risk for severe COVID-19 in addition to the co-morbidities such as diabetes, smoking, hypertension and obesity that often co-exist in these patients.	./cache/cord-307287-zpq6byml.txt	./txt/cord-307287-zpq6byml.txt